# Clonidine - Alpha-2 adrenergic agonist
# FDA-approved for ADHD (Kapvay); limited ADHD-specific approval elsewhere

id: "clonidine"

brandNames:
  US: ["Kapvay", "Catapres"]
  CN: []
  EU: ["Catapres"]
  JP: []
  UK: ["Catapres"]
  AU: ["Catapres"]
  CA: ["Catapres"]

genericName: "clonidine hydrochloride"

manufacturers:
  - name: "Concordia Pharmaceuticals"
    region: "US"
    product: "Kapvay"
  - name: "Boehringer Ingelheim"
    region: "US"
    product: "Catapres"

# Classification
drugClass: "non-stimulant"
category: "alpha-2 adrenergic agonist"
controlledSubstance: false
schedule:
  US: "Not scheduled"
  CN: "Not approved for ADHD"
  EU: "Not scheduled (not ADHD indication)"
  JP: "Not approved for ADHD"
  UK: "Not scheduled"

# Mechanism
activeIngredient: "clonidine hydrochloride"
mechanismOfAction: "Alpha-2 adrenergic receptor agonist. Stimulates presynaptic alpha-2 receptors in the brain, reducing sympathetic outflow and norepinephrine release. In ADHD, thought to improve prefrontal cortex function, reduce hyperactivity, and improve impulse control."
neurotransmittersAffected:
  - norepinephrine

# Dosage & Forms
forms:
  - type: "tablet"
    releaseType: "extended"
    brandName: "Kapvay"
    strengths: ["0.1mg", "0.2mg"]
    durationHours: 12
    notes: "FDA-approved for ADHD; twice daily dosing"

  - type: "tablet"
    releaseType: "immediate"
    brandName: "Catapres"
    strengths: ["0.1mg", "0.2mg", "0.3mg"]
    durationHours: 6-8
    notes: "Approved for hypertension; used off-label for ADHD"

  - type: "patch"
    releaseType: "extended"
    brandName: "Catapres-TTS"
    strengths: ["0.1mg/day", "0.2mg/day", "0.3mg/day"]
    durationHours: 168  # 7 days
    notes: "Transdermal patch; change weekly; off-label for ADHD"

# Efficacy
onsetMinutes: null  # Gradual effect
peakEffectHours: 2-4
durationHours: 6-12

# Side Effects
sideEffects:
  common:
    - name: "somnolence/drowsiness"
      frequency: "30-40%"
    - name: "fatigue"
      frequency: "20-30%"
    - name: "headache"
      frequency: "15-20%"
    - name: "dry mouth"
      frequency: "10-20%"
    - name: "dizziness"
      frequency: "10-15%"
    - name: "irritability"
      frequency: "10%"
    - name: "upper respiratory infection"
      frequency: "10%"

  uncommon:
    - name: "hypotension"
      frequency: "5-10%"
    - name: "bradycardia"
      frequency: "5%"
    - name: "constipation"
      frequency: "5%"
    - name: "nausea"
      frequency: "5%"
    - name: "skin reactions (patch)"
      frequency: "5-15%"

  serious:
    - name: "hypotension"
      notes: "Significant drops in blood pressure possible"
    - name: "bradycardia"
      notes: "Can slow heart rate significantly"
    - name: "rebound hypertension"
      notes: "Severe if stopped abruptly; MUST taper"
    - name: "sedation"
      notes: "Can be profound, especially early in treatment"
    - name: "AV block"
      notes: "Rare cardiac conduction abnormalities"

# Safety
contraindications:
  - "Hypersensitivity to clonidine"
  - "Severe bradyarrhythmia"
  - "Patch: skin irritation at application site"

drugInteractions:
  - drug: "Beta-blockers"
    severity: "major"
    effect: "Enhanced bradycardia, rebound hypertension risk if clonidine stopped"
  - drug: "Tricyclic antidepressants"
    severity: "moderate"
    effect: "May reduce clonidine effectiveness"
  - drug: "CNS depressants"
    severity: "moderate"
    effect: "Enhanced sedation"
  - drug: "Antihypertensives"
    severity: "moderate"
    effect: "Additive hypotensive effect"
  - drug: "Digoxin"
    severity: "moderate"
    effect: "Enhanced AV block risk"

blackBoxWarnings: []

pregnancyCategory: "C"
foodInteractions: "Can be taken with or without food"

# Practical Information
typicalDosing:
  children:
    startingDose: "0.1mg at bedtime"
    maxDose: "0.4mg/day (divided twice daily)"
    notes: "Increase by 0.1mg weekly; Kapvay is twice daily (morning and bedtime)"
  adults:
    startingDose: "0.1mg twice daily"
    maxDose: "0.4mg/day"
    notes: "Off-label for adult ADHD"

costEstimate:
  US:
    brand: "$200-300/month (Kapvay)"
    generic: "$20-50/month"
  CN:
    brand: "Not available for ADHD"
    generic: "Not available for ADHD"

storageRequirements: "Room temperature (25Â°C), protect from light"

# Approval & Availability
approvals:
  - region: "US"
    agency: "FDA"
    year: 2010
    approvedAges: "6-17 years"
    indications:
      - "ADHD"
    available: true
    notes: "Kapvay (ER) approved for ADHD; can be used alone or with stimulants"

  - region: "CN"
    agency: "NMPA"
    year: null
    approvedAges: ""
    indications: []
    available: false
    notes: "Not approved for ADHD"

  - region: "EU"
    agency: "EMA"
    year: null
    approvedAges: ""
    indications: []
    available: false
    notes: "Not specifically approved for ADHD; used off-label"

  - region: "JP"
    agency: "PMDA"
    year: null
    approvedAges: ""
    indications: []
    available: false
    notes: "Not approved for ADHD"

  - region: "UK"
    agency: "MHRA"
    year: null
    approvedAges: ""
    indications: []
    available: false
    notes: "Not specifically approved for ADHD; sometimes used off-label"

# Special Considerations
specialConsiderations:
  cardiacRisk: "Significant cardiovascular effects; monitor BP and HR closely"
  abuseRisk: "No abuse potential; not a controlled substance"
  withdrawalNotes: "CRITICAL: Must taper slowly. Abrupt discontinuation can cause severe rebound hypertension, agitation, and other serious effects"
  monitoringRequired: "Blood pressure and heart rate at each visit; ECG if cardiac concerns"

# Metadata
lastUpdated: 2025-12-02
sources:
  - "https://www.goodrx.com/conditions/adhd/non-stimulant-adhd-meds"
  - "https://www.additudemag.com/adhd-medications-list-chart-stimulants-nonstimulants/"

notes: "Less selective than guanfacine; more sedating. Only FDA-approved for ADHD in US (Kapvay). Helpful for hyperactivity, impulsivity, and sleep issues. Often used as adjunct to stimulants. CRITICAL: Never stop abruptly due to rebound hypertension risk."
